Squarepoint’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-15,554
| Closed | -$19.6K | – | 4451 |
|
|
2025
Q3 | $19.6K | Sell |
15,554
-2,205
| -12% | -$2.38K | ﹤0.01% | 4289 |
|
|
2025
Q2 | $19.9K | Buy |
+17,759
| New | +$20.6K | ﹤0.01% | 4391 |
|
|
2025
Q1 | – | Sell |
-34,295
| Closed | -$56.6K | – | 4834 |
|
|
2024
Q4 | $56.6K | Buy |
34,295
+20,805
| +154% | +$52.4K | ﹤0.01% | 4819 |
|
|
2024
Q3 | $47.2K | Sell |
13,490
-115,269
| -90% | -$449K | ﹤0.01% | 3982 |
|
|
2024
Q2 | $422K | Buy |
+128,759
| New | +$564K | ﹤0.01% | 3205 |
|
|
2024
Q1 | – | Sell |
-176,495
| Closed | -$660K | – | 4187 |
|
|
2023
Q4 | $660K | Sell |
176,495
-98,306
| -36% | -$232K | ﹤0.01% | 2807 |
|
|
2023
Q3 | $583K | Buy |
274,801
+210,582
| +328% | +$698K | ﹤0.01% | 2677 |
|
|
2023
Q2 | $306K | Sell |
64,219
-60,000
| -48% | -$331K | ﹤0.01% | 2956 |
|
|
2023
Q1 | $708K | Sell |
124,219
-471,016
| -79% | -$2.84M | ﹤0.01% | 2105 |
|
|
2022
Q4 | $6.01M | Buy |
+595,235
| New | +$11.2M | 0.02% | 750 |
|
|
2022
Q3 | – | Sell |
-13,207
| Closed | -$327K | – | 3125 |
|
|
2022
Q2 | $327K | Buy |
+13,207
| New | +$364K | ﹤0.01% | 2252 |
|
|
2022
Q1 | – | Sell |
-25,739
| Closed | -$1.51M | – | 3051 |
|
|
2021
Q4 | $1.51M | Sell |
25,739
-72,135
| -74% | -$4.09M | ﹤0.01% | 1428 |
|
|
2021
Q3 | $5.8M | Buy |
97,874
+91,416
| +1,416% | +$7.17M | 0.02% | 708 |
|
|
2021
Q2 | $560K | Sell |
6,458
-8,811
| -58% | -$710K | ﹤0.01% | 2043 |
|
|
2021
Q1 | $1.26M | Buy |
+15,269
| New | +$1.46M | 0.01% | 1343 |
|
|
2020
Q4 | – | Sell |
-12,553
| Closed | -$502K | – | 3012 |
|
|
2020
Q3 | $502K | Sell |
12,553
-54,026
| -81% | -$1.89M | 0.01% | 1431 |
|
|
2020
Q2 | $2.28M | Buy |
66,579
+52,979
| +390% | +$1.58M | 0.04% | 585 |
|
|
2020
Q1 | $302K | Sell |
13,600
-50,301
| -79% | -$1.27M | 0.01% | 1296 |
|
|
2019
Q4 | $1.25M | Sell |
63,901
-103,510
| -62% | -$1.64M | 0.01% | 1199 |
|
|
2019
Q3 | $2.6M | Buy |
167,411
+133,153
| +389% | +$2.55M | 0.02% | 737 |
|
|
2019
Q2 | $695K | Sell |
34,258
-49,515
| -59% | -$892K | 0.01% | 1471 |
|
|
2019
Q1 | $1.47M | Buy |
83,773
+64,078
| +325% | +$1.01M | 0.02% | 904 |
|
|
2018
Q4 | $253K | Sell |
19,695
-35,837
| -65% | -$500K | ﹤0.01% | 1575 |
|
|
2018
Q3 | $905K | Buy |
+55,532
| New | +$657K | 0.01% | 1041 |
|
|
2018
Q1 | – | Sell |
-11,397
| Closed | -$70K | – | 1823 |
|
|
2017
Q4 | $70K | Buy |
+11,397
| New | +$50.9K | ﹤0.01% | 1994 |
|
|
2017
Q3 | – | Sell |
-28,900
| Closed | -$94K | – | 1683 |
|
|
2017
Q2 | $94K | Hold |
28,900
| – | – | ﹤0.01% | 1415 |
|
|
2017
Q1 | $131K | Buy |
28,900
+8,900
| +45% | +$32.6K | ﹤0.01% | 1373 |
|
|
2016
Q4 | $50K | Buy |
+20,000
| New | +$53.5K | ﹤0.01% | 1699 |
|
Other funds holding FATE
RG
JJ
VPC
Squarepoint's FATE Position: Q4 2025 in Review
Squarepoint sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 15,554 shares — an estimated $19.6K sold.
Squarepoint first reported a position in FATE in Q4 2016 and held it in 28 quarters. The position peaked at $6.01M in Q4 2022. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.
- Squarepoint reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
- Squarepoint sold 15,554 Fate Therapeutics shares in Q4 2025, an estimated $19.6K.
- Squarepoint first reported a position in Fate Therapeutics in Q4 2016 and held it in 28 quarters.
- Squarepoint's Fate Therapeutics position peaked at $6.01M in Q4 2022.
- 146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.
Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.